文献速递认知障碍与痴呆帕金森病与运动障碍神经肌肉病

神经退行性疾病医疗保险受益人的临终医疗服务使用与费用

End-of-Life Health Care Service Use and Cost Among Medicare Decedents With Neurodegenerative Diseases.
PubMed 文献 · Neurology · 2024-10-11

美国2018年去世的医疗保险A和B部分受益人中,患有阿尔茨海默病、帕金森病或肌萎缩侧索硬化者与恶性脑肿瘤或胰腺癌死者相比,临终前6个月看神经科医生的比例低,急诊就诊的比值比更高,住院和临终关怀入院的比值比更低。

要点

  • 临终前6个月神经科医生诊疗比例:阿尔茨海默病1.5%、帕金森病8.6%、肌萎缩侧索硬化32.0%。
  • 与恶性脑肿瘤相比,神经退行性疾病患者急诊就诊的调整比值比更高(阿尔茨海默病1.17、帕金森病1.18、肌萎缩侧索硬化1.11)。
  • 与恶性脑肿瘤相比,神经退行性疾病患者住院和临终关怀入院的调整比值比更低。

核心结论

  • 在美国,神经退行性疾病患者比脑肿瘤或胰腺癌患者更可能在临终期就诊急诊,较少使用住院和临终关怀服务。
  • 作者认为这些组间差异可能源于预后不确定性,并反映临终关怀实践不足,需要进一步研究以确保更及时的姑息治疗和临终关怀转诊。

研究设计与样本

  • 回顾性研究,纳入2018年去世的医疗保险A和B部分受益人,患有阿尔茨海默病、帕金森病或肌萎缩侧索硬化者,以恶性脑肿瘤或胰腺癌死者为非神经退行性疾病对照。
  • 2018年共有1,126,799名医疗保险受益人去世,其中357,926人具有符合条件的诊断。
  • 采用描述性分析考察临终最后一年的人口学和临床特征,并比较最后12个月和6个月急诊、住院、熟练护理机构和临终关怀使用的概率及相关费用,调整社会人口学因素和合并症负担。

主要发现

  • 神经退行性疾病患者比脑肿瘤或胰腺癌患者年龄更大,且更常接受医疗补助。
  • 所有组别在临终最后一年医疗服务使用均增加,总费用主要归因于住院护理。
  • 临终前6个月神经科医生诊疗比例:阿尔茨海默病1.5%、帕金森病8.6%、肌萎缩侧索硬化32.0%。
  • 与恶性脑肿瘤相比,神经退行性疾病患者急诊就诊的调整比值比更高:阿尔茨海默病1.17(95%CI 1.11-1.23)、帕金森病1.18(95%CI 1.11-1.25)、肌萎缩侧索硬化1.11(95%CI 1.01-1.23);住院的调整比值比更低:阿尔茨海默病0.64(95%CI 0.60-0.68)、帕金森病0.65(95%CI 0.61-0.69)、肌萎缩侧索硬化0.33(95%CI 0.30-0.37);临终关怀入院的调整比值比更低:阿尔茨海默病0.33(95%CI 0.31-0.36)、帕金森病0.33(95%CI 0.31-0.36)、肌萎缩侧索硬化0.41(95%CI 0.36-0.46)。
  • 与胰腺癌比较的结果相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Although neurodegenerative diseases are a leading cause of death, little is known about health care utilization and cost during the end-of-life (EoL) period or how it compares with that of other life-limiting conditions. We aimed to describe and compare resource utilization among US Medicare decedents with neurodegenerative diseases with decedents with cancer. METHODS: We conducted a retrospective study of Medicare Part A and B beneficiaries with Alzheimer disease (AD), Parkinson disease (PD), or amyotrophic lateral sclerosis (ALS) who died in 2018. Decedents diagnosed with malignant brain tumors or pancreatic cancer served as non-neurodegenerative comparators. Descriptive analyses examined demographic and clinical characteristics in the last year of life. The probabilities and associated costs of emergency department (ED), inpatient, skilled nursing facility (SNF), and hospice utilization during the last 12 and 6 months of life were also compared between persons with neurodegenerative diseases and cancer, adjusting for sociodemographic factors and comorbidity burden. RESULTS: A total of 1,126,799 Medicare beneficiaries died in 2018, of which 357,926 had a qualifying diagnosis. Persons with neurodegenerative diseases were older and more frequently received Medicaid assistance than persons with brain or pancreatic cancer. In all groups, health care service utilization increased over the last year of life, and total costs were predominantly attributable to inpatient care. In the last 6 months of life, neurologist care was infrequent among patients with neurodegenerative disease (AD: 1.5%; PD: 8.6%; ALS: 32.0%). Persons with neurodegenerative diseases as compared to persons with malignant brain tumors also had greater odds of ED use (AD: adjusted odds ratio [aOR] 1.17, 95% CI 1.11-1.23; PD: aOR 1.18, 95% CI 1.11-1.25; ALS: aOR 1.11, 95% CI 1.01-1.23), lower odds of hospitalization (AD: aOR 0.64, 95% CI 0.60-0.68; PD: aOR 0.65, 95% CI 0.61-0.69; ALS: aOR 0.33, 95% CI 0.30-0.37), and lower odds of hospice enrollment (AD: aOR 0.33, 95% CI 0.31-0.36; PD: aOR 0.33, 95% CI 0.31-0.36; ALS: aOR 0.41, 95% CI 0.36-0.46). The findings were similar in pancreatic cancer. DISCUSSION: Persons with neurodegenerative diseases in the United States are more likely to visit the ED and less likely to use inpatient and hospice services at EoL than persons with brain or pancreatic cancer. These group differences may stem from prognostic uncertainty and reflect inadequate EoL care practices, requiring further investigation to ensure more timely palliative care and hospice referrals.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Aamodt WW, Sun C, Dahodwala N, et al. End-of-Life Health Care Service Use and Cost Among Medicare Decedents With Neurodegenerative Diseases. Neurology. 2024. PMID: 39393030. doi:10.1212/WNL.0000000000209925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。